Redhill Property Plant Equipment vs Non Currrent Assets Other Analysis
RDHL Stock | USD 6.78 0.04 0.59% |
Redhill Biopharma financial indicator trend analysis is much more than just breaking down Redhill Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Redhill Biopharma is a good investment. Please check the relationship between Redhill Biopharma Property Plant Equipment and its Non Currrent Assets Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Property Plant Equipment vs Non Currrent Assets Other
Property Plant Equipment vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Redhill Biopharma Property Plant Equipment account and Non Currrent Assets Other. At this time, the significance of the direction appears to have very week relationship.
The correlation between Redhill Biopharma's Property Plant Equipment and Non Currrent Assets Other is 0.22. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Redhill Biopharma, assuming nothing else is changed. The correlation between historical values of Redhill Biopharma's Property Plant Equipment and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Redhill Biopharma are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Property Plant Equipment i.e., Redhill Biopharma's Property Plant Equipment and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.22 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Property Plant Equipment
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Redhill Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 9.28 this year, although the value of Issuance Of Capital Stock will most likely fall to about 13.3 M.
Redhill Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Redhill Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Redhill Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 74.1M | 180.2M | 181.2M | 158.9M | 23.0M | 21.9M | |
Other Current Liab | 107K | 60.0M | 68.2M | 77.0M | 15.2M | 19.1M | |
Total Current Liabilities | 10.6M | 73.2M | 81.5M | 197.5M | 19.2M | 33.1M | |
Other Liab | 844K | 500K | 7.9M | 4.6M | 5.3M | 2.8M | |
Accounts Payable | 4.2M | 11.6M | 11.7M | 4.2M | 3.3M | 4.2M | |
Cash | 29.0M | 29.3M | 29.5M | 20.0M | 5.6M | 5.3M | |
Common Stock Shares Outstanding | 742.3K | 910.7K | 1.2M | 1.5M | 6.5M | 6.8M | |
Short Term Investments | 24.2M | 18.8M | 498K | 8.5M | 790.0K | 750.5K | |
Other Current Assets | 2.2M | 4.9M | 3.8M | 17.0M | 2.1M | 2.0M | |
Total Liab | 14.1M | 166.4M | 172.3M | 207.3M | 21.0M | 19.9M | |
Intangible Assets | 16.9M | 87.9M | 71.6M | 65.6M | 5.6M | 5.3M | |
Common Stock | 962K | 1.1M | 1.5M | 2.8M | 21.4M | 22.5M | |
Property Plant Equipment | 163K | 3.8M | 5.7M | 4.2M | 4.9M | 5.1M | |
Total Stockholder Equity | 60.0M | 13.9M | 8.9M | (48.4M) | 2.1M | 2.0M | |
Property Plant And Equipment Net | 3.8M | 5.7M | 4.2M | 7.2M | 1.2M | 2.0M | |
Net Debt | (25.2M) | 57.6M | 58.3M | 102.7M | (4.4M) | (4.2M) | |
Retained Earnings | (208.4M) | (280.3M) | (367.9M) | (433.9M) | (407.7M) | (387.4M) | |
Non Current Assets Total | 20.9M | 109.7M | 92.0M | 73.0M | 6.9M | 6.6M | |
Non Currrent Assets Other | (20.7M) | 16.2M | 16.2M | 150K | 41.0 | 38.95 | |
Cash And Short Term Investments | 47.9M | 29.8M | 38.0M | 20.0M | 6.4M | 6.0M | |
Net Receivables | 1.2M | 29.3M | 32.5M | 37.9M | 3.3M | 3.1M | |
Common Stock Total Equity | 575K | 767K | 962K | 1.1M | 1.2M | 1.3M | |
Liabilities And Stockholders Equity | 74.1M | 180.2M | 181.2M | 158.9M | 23.0M | 21.9M | |
Non Current Liabilities Total | 3.5M | 93.1M | 90.8M | 9.8M | 1.7M | 1.6M | |
Inventory | 1.9M | 6.5M | 14.8M | 11.0M | 4.4M | 4.6M | |
Other Stockholder Equity | 267.4M | 293.1M | 375.2M | 382.6M | 388.4M | 217.0M | |
Property Plant And Equipment Gross | 3.8M | 5.7M | 5.0M | 8.3M | 2.4M | 2.2M | |
Total Current Assets | 53.2M | 70.5M | 89.2M | 85.9M | 16.1M | 15.3M | |
Net Tangible Assets | 45.9M | 43.1M | (74.0M) | (62.8M) | (56.5M) | (53.7M) | |
Net Invested Capital | 60.0M | 95.3M | 92.5M | 66.8M | 2.1M | 2.0M | |
Net Working Capital | 42.6M | (2.7M) | 7.7M | (111.6M) | (3.1M) | (2.9M) | |
Capital Stock | 962K | 1.1M | 1.5M | 2.8M | 21.4M | 22.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.